{"created":"2023-05-15T16:30:44.805014+00:00","id":1989,"links":{},"metadata":{"_buckets":{"deposit":"45785ab7-6f45-4285-a289-56c711c6a3a0"},"_deposit":{"created_by":2,"id":"1989","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"1989"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00001989","sets":["10:11"]},"author_link":["9188","9189","9191","9190"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-05-26","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageStart":"2578","bibliographicVolumeNumber":"20","bibliographic_titles":[{"bibliographic_title":"International Journal of Molecular Sciences"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the\nfirst-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing  50% expression of programmed death-ligand 1 (PD-L1). Previously it was reported that platinum-based chemotherapy may change PD-L1 expression in solid cancers. However, no reports addressing alteration of PD-L1 expression after ICI therapy in NSCLC are available so far. The patients were\nJapanesemales 83 and 87 years old,whowere diagnosedwithNSCLC based on the transbronchial lung biopsies showing sarcomatoid feature with high PD-L1 expression. They received Pembrolizumab,\nhowever, passed awaywith disease progression on day 27 and day 9, respectively. PD-L1, PD1, andCD8 antibodies were applied to pretreatment tumor biopsies and autopsy specimens. Immunoexpression of all themarkers was evaluated using Aperio ImageScope. We found that PD-L1 expression decreased significantly from 75.6% to 13.2% and from 100% to 58.8%, in patients 1 and 2, respectively. This alteration was less prominent in the perinecrotic tumor area. A considerable decrease of PD-L1 score was linked with a little effect of Pembrolizumab in our patients. This association might be one of the contributing mechanisms of resistance to ICI and needs further investigation in large-scale studies.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"International journal of molecular sciences, 20(10), art.no.2578; 2019","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/ijms20102578","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"16616596","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"14220067","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takahashi, Toshiaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tateishi, Akiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Bychkov, Andrey"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukuoka, Junya"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"IJMS20_2578.pdf","filesize":[{"value":"2.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"IJMS20_2578.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/1989/files/IJMS20_2578.pdf"},"version_id":"3c226a49-2baa-43b0-905e-1642016f6111"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"NSCLC","subitem_subject_scheme":"Other"},{"subitem_subject":"immune therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Pembrolizumab","subitem_subject_scheme":"Other"},{"subitem_subject":"immune checkpoint inhibitors","subitem_subject_scheme":"Other"},{"subitem_subject":"PD-L1","subitem_subject_scheme":"Other"},{"subitem_subject":"tumor microenvironment","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports"}]},"item_type_id":"2","owner":"2","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-07-02"},"publish_date":"2019-07-02","publish_status":"0","recid":"1989","relation_version_is_last":true,"title":["Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:54:25.409301+00:00"}